HighTower Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
HighTower Advisors's VRTX Position: Q2 2026 in Review
HighTower Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, selling an estimated $7.39M and leaving 49,020 shares worth $24.3M. The position accounts for 0.02% of the portfolio, ranked #586.
HighTower Advisors first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.4M in Q4 2023. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- HighTower Advisors held 49,020 shares of Vertex Pharmaceuticals worth $24.3M as of Q2 2026.
- HighTower Advisors sold 16,664 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.39M.
- Vertex Pharmaceuticals made up 0.02% of HighTower Advisors's portfolio in Q2 2026, its #586 holding.
- HighTower Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- HighTower Advisors's Vertex Pharmaceuticals position peaked at $33.4M in Q4 2023.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.